default author photo

Juxiang Xiao

Xi'an Jiaotong University (XJTU) - First Affiliated Hospital

26 Xianning W Rd.

Xi'an, Shaanxi 710049

China

SCHOLARLY PAPERS

1

DOWNLOADS

183

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Anlotinib for Previously Treated Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ALTER1102): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial

Number of pages: 26 Posted: 28 Jul 2019
Chinese Academy of Medical Sciences - Cancer Hospital, Xi'an Jiaotong University (XJTU) - First Affiliated Hospital, Shanghai Jiao Tong University (SJTU) - Shanghai Chest Hospital, Xinxiang Medical University - First Affiliated Hospital, Zhengzhou University - First Affiliated Hospital, Nanjing Medical University - First Affiliated Hospital, Nanjing Medical University - Jiangsu Institute of Cancer Research, Shandong University - Shandong Cancer Hospital, Tianjin Cancer Hospital, Nanjing Medical University - Department of Epidemiology and Biostatistics, Zhengzhou University - Henan Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Peking Union Medical College Hospital, Harbin Medical University - Cancer Hospital, Xinjiang Medical University - Affiliated Tumor Hospital, Chinese Academy of Medical Sciences - Department of Medical Oncology and Chinese Academy of Medical Sciences & Peking Union Medical College - Thoracic Surgery Department
Downloads 183 (413,774)

Abstract:

Loading...

esophageal squamous cell carcinoma; metastatic; anlotinib; survival; progression-free survival; adverse events